Identification

Name
Hydrocodone
Accession Number
DB00956  (APRD00591, DB09475)
Type
Small Molecule
Groups
Approved, Illicit
Description

Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant.

Structure
Thumb
Synonyms
  • (-)-Dihydrocodeinone
  • 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
  • Dihydrocodeinone
  • Hidrocodona
  • Hydrocodon
  • Hydrocodone polistirex
  • Hydrocodonum
  • Hydrocone
  • Hydroconum
  • Idrocodone
External IDs
NSC-19044
Product Ingredients
IngredientUNIICASInChI Key
Hydrocodone bitartrateNO70W886KK34195-34-1JMBRWJAVUIITGV-LNNMZZBZSA-N
Hydrocodone hydrochlorideQKZ0920OV325968-91-6GCJAEXSZUXBMFS-RNWHKREASA-N
Hydrocodone polistirexNot AvailableNot AvailableNot applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hycodan SyrupSyrup5 mgOralBristol Myers Squibb1992-12-31Not applicableCanada
Hycodan TabletsTablet5 mgOralBristol Myers Squibb1992-12-31Not applicableCanada
Hysingla ERTablet, extended release80 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release30 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release120 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release60 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release20 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release100 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release40 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Robidone 1mg/ml SyrSyrup1 mgOralWyeth Ayerst Canada Inc.1993-12-312001-11-06Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydrocodone Bitartrate And AcetaminophenTablet5 mg/1OralRemedy Repack2013-03-132017-04-14Us
Hydrocodone Bitartrate And AcetaminophenTablet5 mg/1OralRemedy Repack2013-02-202016-10-13Us
Hydrocodone Bitartrate and AcetaminophenTablet5 mg/1OralRemedy Repack2013-03-182016-10-13Us
Pdp-hydrocodoneSyrup5 mgOralPendopharm Division Of De Pharmascience Inc2009-03-21Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Caldomine Dh AdulteHydrocodone bitartrate (5 mg) + Mepyramine maleate (12.5 mg) + Pheniramine maleate (12.5 mg) + Phenylpropanolamine hydrochloride (25 mg)LiquidOralTechnilab Pharma Inc.1981-12-312001-04-04Canada
Caldomine Dh EnfantHydrocodone bitartrate (1.667 mg) + Mepyramine maleate (6.25 mg) + Pheniramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg)LiquidOralTechnilab Pharma Inc.1982-12-312001-04-04Canada
CodofenHydrocodone bitartrate (7.5 mg) + Ibuprofen (200 mg)TabletOralPaladin Labs IncNot applicableNot applicableCanada
Coristine-DH LiqHydrocodone bitartrate (1.7 mg) + Phenylephrine hydrochloride (10 mg)SyrupOralTechnilab Pharma Inc.1988-12-312006-07-28Canada
DalmacolHydrocodone bitartrate (1.65 mg) + Doxylamine succinate (6 mg) + Etafedrine hydrochloride (16.65 mg) + Ethanol (0.25 ml) + Sodium Citrate (200 mg)SyrupOralLaboratoire Riva Inc1997-03-26Not applicableCanada
DalmacolHydrocodone bitartrate (1.65 mg) + Doxylamine succinate (6 mg) + Etafedrine hydrochloride (16.65 mg) + Ethanol (0.25 ml) + Sodium Citrate (200 mg)SyrupOralLaboratoire Atlas Inc1983-12-31Not applicableCanada
Dimetane Expectorant DcHydrocodone bitartrate (1.8 mg) + Brompheniramine maleate (2 mg) + Guaifenesin (100 mg) + Phenylephrine hydrochloride (5 mg)SyrupOralPfizer Laboratories Div Pfizer Inc.2001-09-06Not applicableCanada
Dimetane Expectorant-DC SyrHydrocodone bitartrate (1.8 mg) + Brompheniramine maleate (2 mg) + Guaifenesin (100 mg) + Phenylephrine hydrochloride (5 mg) + Phenylpropanolamine hydrochloride (5 mg)SyrupOralWhitehall Robins Inc.1993-12-312001-04-10Canada
FlowtussHydrocodone bitartrate (2.5 mg/5mL) + Guaifenesin (200 mg/5mL)LiquidOralMission Pharmacal2015-08-18Not applicableUs
HycetHydrocodone bitartrate (7.5 mg/15mL) + Acetaminophen (325 mg/15mL)SolutionOralGw Pharmaceuticals Ltd.2011-02-01Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Theracodophen-325Hydrocodone bitartrate + Acetaminophen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-082016-10-13Us
Theracodophen-650Hydrocodone bitartrate + Acetaminophen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-03-062016-10-13Us
Theracodophen-750Hydrocodone + Acetaminophen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-092016-10-13Us
Theracodophen-Low-90Hydrocodone bitartrate + Acetaminophen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-022016-10-13Us
Topical PainHydrocodone (.1 g/100mL) + Diazepam (.1 g/100mL) + Ibuprofen (.1 g/100mL) + Tramadol (.1 g/100mL)CreamTopicalDr Marc's Manufacturing And Sales2016-02-232018-05-11Us
Categories
UNII
6YKS4Y3WQ7
CAS number
125-29-1
Weight
Average: 299.3642
Monoisotopic: 299.152143543
Chemical Formula
C18H21NO3
InChI Key
LLPOLZWFYMWNKH-CMKMFDCUSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O

Pharmacology

Indication

For relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.

Associated Conditions
Pharmacodynamics

Hydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine. Opiate agonists exert their principal pharmacologic effect at specific receptor binding sites in the CNS and other tissues. There are several subtypes of opiate receptors including the mu receptor (localized in pain modulating regions of the CNS), the kappa receptor (localized in the deep layers of the cerebral cortex), the delta receptor (localized in the limbic regions of the CNS), and the sigma receptor (thought to mediate the dysphoric and psychotomimetic effects of some opiate partial agonists). Agonist activity at the mu or kappa receptor can result in analgesia, miosis, and/or decreased body temperature. Agonist activity at the mu receptor can also result in suppression of opiate withdrawal, whereas antagonist activity can result in precipitation of withdrawal. Opiate agonists act at several sites within the CNS involving several systems of neurotransmitters to produce analgesia, but the precise mechanism of action has not been fully determined. Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli nor the conduction of impulses along peripheral nerves. Instead, they alter the perception of pain at the spinal cord and higher levels in the CNS and the person's emotional response to pain.

Mechanism of action

Hydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
Absorption

Well absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% Hydromorphone to 45% Oxycodone), hydrocodone is expected to fall within this range.

Metabolism

Hepatic and also in intestinal mucosa.

Route of elimination
Not Available
Half life

1.25-3 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD50=85.7mg/kg (subcutaneous, in mice).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Hydrocodone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when (2-benzhydryloxyethyl)diethyl-methylammonium iodide is combined with Hydrocodone.Experimental
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
4-Methoxyamphetamine4-Methoxyamphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamine5-methoxy-N,N-dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
6-Deoxyerythronolide BThe metabolism of Hydrocodone can be decreased when combined with 6-Deoxyerythronolide B.Experimental
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AbirateroneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Abiraterone resulting in a loss in efficacy.Approved
AcalabrutinibThe metabolism of Hydrocodone can be decreased when combined with Acalabrutinib.Approved, Investigational
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Acetylglycinamide chloral hydrateAcetylglycinamide chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydrocodone.Approved
AdinazolamAdinazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AdipiplonAdipiplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
AgmatineThe risk or severity of adverse effects can be increased when Agmatine is combined with Hydrocodone.Experimental, Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AlaproclateAlaproclate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AlcuroniumAlcuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
AllobarbitalAllobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AllopregnanoloneAllopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AlosetronAlosetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
AlphaprodineAlphaprodine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
AlverineAlverine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alvimopan.Approved, Investigational
AmantadineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Amantadine.Approved
AmikacinAmikacin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
AmilorideThe therapeutic efficacy of Amiloride can be decreased when used in combination with Hydrocodone.Approved
AmineptineAmineptine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Withdrawn
AmiodaroneThe metabolism of Hydrocodone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AmitriptylinoxideAmitriptylinoxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AmlodipineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Amlodipine resulting in a loss in efficacy.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Hydrocodone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AmphetamineAmphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
Amphotericin BThe metabolism of Hydrocodone can be decreased when combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Hydrocodone can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamAniracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydrocodone.Approved
ApalutamideThe serum concentration of Hydrocodone can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791APD791 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ApomorphineApomorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ApramycinApramycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Vet Approved
AprepitantThe metabolism of Hydrocodone can be decreased when combined with Aprepitant.Approved, Investigational
AprobarbitalAprobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ApronalideApronalide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Arbaclofen PlacarbilArbaclofen Placarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ArbekacinArbekacin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Aripiprazole lauroxilAripiprazole lauroxil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ArmodafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Armodafinil.Approved, Investigational
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AsunaprevirThe serum concentration of Hydrocodone can be decreased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Hydrocodone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Hydrocodone can be decreased when combined with Atomoxetine.Approved
AtracuriumAtracurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Hydrocodone.Approved, Vet Approved
AvasimibeThe serum concentration of Hydrocodone can be decreased when it is combined with Avasimibe.Investigational
AVE9633The metabolism of Hydrocodone can be decreased when combined with AVE9633.Investigational
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Vet Approved
AZD-3043AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
AzelastineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Hydrocodone.Investigational
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BarbexacloneBarbexaclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Barbituric acid derivative is combined with Hydrocodone.Experimental, Illicit
BeclamideBeclamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Beclomethasone dipropionateThe serum concentration of Hydrocodone can be decreased when it is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
BenactyzineBenactyzine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Hydrocodone.Approved
BenmoxinBenmoxin may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydrocodone.Approved
BenziloneThe risk or severity of adverse effects can be increased when Benzilone is combined with Hydrocodone.Experimental
BenzoctamineBenzoctamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BenzphetamineBenzphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
BenzquinamideThe risk or severity of adverse effects can be increased when Benzquinamide is combined with Hydrocodone.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Hydrocodone.Approved
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BetamethasoneThe serum concentration of Hydrocodone can be decreased when it is combined with Betamethasone.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Hydrocodone.Experimental
BexaroteneThe serum concentration of Hydrocodone can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Bezitramide.Experimental, Illicit, Withdrawn
BicalutamideThe metabolism of Hydrocodone can be decreased when combined with Bicalutamide.Approved
BifemelaneBifemelane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
BifeprunoxBifeprunox may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydrocodone.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Hydrocodone.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Hydrocodone.Approved
BL-1020BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
BlonanserinBlonanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BoceprevirThe metabolism of Hydrocodone can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Hydrocodone.Experimental
BortezomibThe metabolism of Hydrocodone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Hydrocodone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe metabolism of Hydrocodone can be decreased when combined with Bosutinib.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Botulinum Toxin Type BBotulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Brefeldin AThe metabolism of Hydrocodone can be decreased when combined with Brefeldin A.Experimental
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BrigatinibThe serum concentration of Hydrocodone can be decreased when it is combined with Brigatinib.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BrinzolamideThe therapeutic efficacy of Brinzolamide can be decreased when used in combination with Hydrocodone.Approved
BrivaracetamBrivaracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BrofaromineBrofaromine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
BromisovalBromisoval may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
BromocriptineBromocriptine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BromotheophyllineThe therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Hydrocodone.Approved
BromperidolBromperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
Bryostatin 1The metabolism of Hydrocodone can be decreased when combined with Bryostatin 1.Investigational
BuclizineThe risk or severity of adverse effects can be increased when Buclizine is combined with Hydrocodone.Approved
BudesonideThe serum concentration of Hydrocodone can be decreased when it is combined with Budesonide.Approved
BufotenineBufotenine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Hydrocodone.Approved
BuprenorphineThe metabolism of Hydrocodone can be decreased when combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionBupropion may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButaperazineButaperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Hydrocodone.Approved, Investigational, Vet Approved
CabergolineCabergoline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CamazepamCamazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Camylofin is combined with Hydrocodone.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocodone.Approved
CandicidinThe metabolism of Hydrocodone can be decreased when combined with Candicidin.Withdrawn
CannabidiolCannabidiol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
CannabidivarinCannabidivarin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Canrenoic acidThe therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Hydrocodone.Approved, Withdrawn
CanrenoneThe therapeutic efficacy of Canrenone can be decreased when used in combination with Hydrocodone.Investigational
CapreomycinCapreomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CaptodiameCaptodiame may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CarbomycinThe metabolism of Hydrocodone can be decreased when combined with Carbomycin.Vet Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Hydrocodone.Approved, Investigational
CarbromalCarbromal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Investigational, Vet Approved
CariprazineCariprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
CarisbamateCarisbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CaroxazoneCaroxazone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
CarteololThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Carteolol resulting in a loss in efficacy.Approved
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Hydrocodone.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneCathinone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
CelecoxibThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Celecoxib resulting in a loss in efficacy.Approved, Investigational
CeritinibThe metabolism of Hydrocodone can be decreased when combined with Ceritinib.Approved
CerlapirdineCerlapirdine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
CethromycinThe metabolism of Hydrocodone can be decreased when combined with Cethromycin.Investigational
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Hydrocodone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Hydrocodone.Approved
ChloroquineChloroquine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Hydrocodone.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ChlorphenesinChlorphenesin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydrocodone.Withdrawn
ChlorphentermineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
ChlortetracyclineChlortetracycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Hydrocodone.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CholecalciferolThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cholecalciferol resulting in a loss in efficacy.Approved, Nutraceutical
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Hydrocodone.Investigational
CilansetronCilansetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
CimetidineThe metabolism of Hydrocodone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cinacalcet resulting in a loss in efficacy.Approved
CinitaprideCinitapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
CinolazepamCinolazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CisaprideCisapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
CisatracuriumCisatracurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CitalopramCitalopram may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClarithromycinThe metabolism of Hydrocodone can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClindamycinClindamycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClobetasolThe serum concentration of Hydrocodone can be decreased when it is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe serum concentration of Hydrocodone can be decreased when it is combined with Clobetasol propionate.Approved
ClofenamideThe therapeutic efficacy of Clofenamide can be decreased when used in combination with Hydrocodone.Experimental
ClofibrateThe serum concentration of Hydrocodone can be decreased when it is combined with Clofibrate.Approved, Investigational
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ClomocyclineClomocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClopamideThe therapeutic efficacy of Clopamide can be decreased when used in combination with Hydrocodone.Experimental
ClopenthixolClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClorexoloneThe therapeutic efficacy of Clorexolone can be decreased when used in combination with Hydrocodone.Experimental
ClothiapineClothiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ClotiazepamClotiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClotrimazoleThe metabolism of Hydrocodone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamCloxazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CobicistatThe metabolism of Hydrocodone can be decreased when combined with Cobicistat.Approved
CocaineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cocaine resulting in a loss in efficacy.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ColistimethateColistimethate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ColistinColistin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Coltuximab ravtansineThe metabolism of Hydrocodone can be decreased when combined with Coltuximab ravtansine.Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Hydrocodone.Approved, Investigational
CorticotropinThe serum concentration of Hydrocodone can be decreased when it is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe metabolism of Hydrocodone can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Hydrocodone can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineCyamemazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CyclobarbitalCyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Hydrocodone.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydrocodone.Approved
CyclopropaneCyclopropane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
CyclosporineThe metabolism of Hydrocodone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Hydrocodone.Approved
CycrimineThe risk or severity of adverse effects can be increased when Cycrimine is combined with Hydrocodone.Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Cyproterone acetateThe metabolism of Hydrocodone can be decreased when combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalfopristinThe metabolism of Hydrocodone can be decreased when combined with Dalfopristin.Approved
DanazolThe metabolism of Hydrocodone can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Hydrocodone.Approved, Investigational, Withdrawn
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrocodone.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DapoxetineDapoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
DarifenacinThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Darifenacin resulting in a loss in efficacy.Approved, Investigational
DarunavirThe metabolism of Hydrocodone can be decreased when combined with Darunavir.Approved
DasatinibThe metabolism of Hydrocodone can be decreased when combined with Dasatinib.Approved, Investigational
DeanolDeanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DecamethoniumDecamethonium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DeferasiroxThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Hydrocodone can be decreased when combined with Delavirdine.Approved
DelorazepamDelorazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
DemeclocyclineDemeclocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DeramciclaneDeramciclane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DesmopressinThe risk or severity of hyponatremia can be increased when Hydrocodone is combined with Desmopressin.Approved
DesogestrelThe metabolism of Hydrocodone can be decreased when combined with Desogestrel.Approved
DesonideThe serum concentration of Hydrocodone can be decreased when it is combined with Desonide.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
DexamethasoneThe metabolism of Hydrocodone can be decreased when combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe metabolism of Hydrocodone can be decreased when combined with Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydrocodone.Withdrawn
DexfenfluramineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Dexfenfluramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DexmethylphenidateDexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DextofisopamDextofisopam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
DextroamphetamineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanDextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Vet Approved
DibekacinDibekacin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DibenzepinDibenzepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DichloralphenazoneDichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DiclofenamideThe therapeutic efficacy of Diclofenamide can be decreased when used in combination with Hydrocodone.Approved, Investigational
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.Approved
Diethyl etherDiethyl ether may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DiethylpropionThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Diethylpropion.Approved, Illicit
DifemerineThe risk or severity of adverse effects can be increased when Difemerine is combined with Hydrocodone.Experimental
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DihexyverineThe risk or severity of adverse effects can be increased when Dihexyverine is combined with Hydrocodone.Experimental
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Vet Approved
DiltiazemThe metabolism of Hydrocodone can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DimetacrineDimetacrine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
DimethyltryptamineDimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Dimetindene is combined with Hydrocodone.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Diphemanil is combined with Hydrocodone.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Hydrocodone.Approved, Vet Approved, Withdrawn
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Diphenidol is combined with Hydrocodone.Approved, Investigational, Withdrawn
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DirithromycinThe metabolism of Hydrocodone can be decreased when combined with Dirithromycin.Approved, Investigational
DisopyramideThe risk or severity of adverse effects can be increased when Disopyramide is combined with Hydrocodone.Approved
DixyrazineDixyrazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Hydrocodone.Approved
DolasetronDolasetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Domoic AcidDomoic Acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DonepezilDonepezil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DoramectinThe metabolism of Hydrocodone can be decreased when combined with Doramectin.Vet Approved
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Hydrocodone.Approved
DosulepinDosulepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DotarizineDotarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
DovitinibThe metabolism of Hydrocodone can be decreased when combined with Dovitinib.Investigational
DoxacuriumDoxacurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DoxefazepamDoxefazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DoxycyclineThe metabolism of Hydrocodone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DronedaroneThe metabolism of Hydrocodone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DrospirenoneThe serum concentration of Hydrocodone can be decreased when it is combined with Drospirenone.Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DuloxetineDuloxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EdivoxetineEdivoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EfavirenzThe metabolism of Hydrocodone can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Hydrocodone.Approved, Investigational
EletriptanEletriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EltanoloneEltanolone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EltoprazineEltoprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EluxadolineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Eluxadoline.Approved, Investigational
EmeproniumEmepronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocodone.Approved
EmylcamateEmylcamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EnzalutamideThe serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.Approved
EperisoneEperisone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EpinastineEpinastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Hydrocodone.Experimental
EplerenoneThe therapeutic efficacy of Eplerenone can be decreased when used in combination with Hydrocodone.Approved
EplivanserinEplivanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EpofolateThe metabolism of Hydrocodone can be decreased when combined with Epofolate.Investigational
Epothilone DThe metabolism of Hydrocodone can be decreased when combined with Epothilone D.Experimental, Investigational
EprinomectinThe metabolism of Hydrocodone can be decreased when combined with Eprinomectin.Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ErgonovineErgonovine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ErgotamineErgotamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ErtugliflozinThe therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Hydrocodone.Approved, Investigational
ErythromycinThe metabolism of Hydrocodone can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Eslicarbazepine acetateEslicarbazepine acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EsmirtazapineEsmirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EsreboxetineEsreboxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EstradiolThe serum concentration of Hydrocodone can be decreased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Etacrynic acidEtacrynic acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Hydrocodone.Experimental
EthadioneEthadione may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydrocodone.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthoxzolamideThe therapeutic efficacy of Ethoxzolamide can be decreased when used in combination with Hydrocodone.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
Ethyl chlorideEthyl chloride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Withdrawn
EtiracetamEtiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtoperidoneEtoperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Vet Approved
EtravirineThe serum concentration of Hydrocodone can be decreased when it is combined with Etravirine.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Hydrocodone.Experimental
EverolimusThe metabolism of Hydrocodone can be decreased when combined with Everolimus.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FabomotizoleFabomotizole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Fazadinium bromideFazadinium bromide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
FebarbamateFebarbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FelodipineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Felodipine resulting in a loss in efficacy.Approved, Investigational
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
FenfluramineFenfluramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Withdrawn
FenpiveriniumThe risk or severity of adverse effects can be increased when Fenpiverinium is combined with Hydrocodone.Experimental
FenquizoneThe therapeutic efficacy of Fenquizone can be decreased when used in combination with Hydrocodone.Experimental
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Vet Approved
FenyramidolFenyramidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Hydrocodone.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FluanisoneFluanisone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
FluconazoleThe metabolism of Hydrocodone can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FludrocortisoneThe serum concentration of Hydrocodone can be decreased when it is combined with Fludrocortisone.Approved, Investigational
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlunisolideThe serum concentration of Hydrocodone can be decreased when it is combined with Flunisolide.Approved, Investigational
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Hydrocodone can be decreased when it is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluoxetineThe metabolism of Hydrocodone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
FlurithromycinThe metabolism of Hydrocodone can be decreased when combined with Flurithromycin.Experimental
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FluticasoneThe metabolism of Hydrocodone can be decreased when combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe metabolism of Hydrocodone can be decreased when combined with Fluticasone furoate.Approved
Fluticasone propionateThe metabolism of Hydrocodone can be decreased when combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Hydrocodone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Hydrocodone can be decreased when it is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Hydrocodone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe metabolism of Hydrocodone can be decreased when combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
FostamatinibThe metabolism of Hydrocodone can be decreased when combined with Fostamatinib.Approved, Investigational
FramycetinFramycetin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FrovatriptanFrovatriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Hydrocodone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Hydrocodone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
GaboxadolGaboxadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
GallamineGallamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
Gantacurium ChlorideGantacurium Chloride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
GedocarnilGedocarnil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
GeneticinGeneticin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
GenisteinThe serum concentration of Hydrocodone can be decreased when it is combined with Genistein.Investigational
GentamicinGentamicin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
GepefrineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Gepefrine.Experimental
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Hydrocodone.Approved, Investigational
Glycerol PhenylbutyrateThe serum concentration of Hydrocodone can be decreased when it is combined with Glycerol Phenylbutyrate.Approved
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydrocodone.Approved, Investigational, Vet Approved
GPI-1485The metabolism of Hydrocodone can be decreased when combined with GPI-1485.Investigational
GranisetronGranisetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
HeptabarbitalHeptabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HexafluroniumHexafluronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HexamethoniumHexamethonium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
HexapropymateHexapropymate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Hexocyclium is combined with Hydrocodone.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydrocodone.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Homatropine Methylbromide is combined with Hydrocodone.Approved
HydracarbazineHydracarbazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Hydrocodone.Approved, Vet Approved
HydrocortisoneThe metabolism of Hydrocodone can be decreased when combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone aceponateThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Hydrocodone.Approved, Investigational
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxyamphetamineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Hygromycin BHygromycin B may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydrocodone.Approved
HypericinHypericin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
IbopamineThe therapeutic efficacy of Ibopamine can be decreased when used in combination with Hydrocodone.Experimental
IdalopirdineIdalopirdine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
IdelalisibThe metabolism of Hydrocodone can be decreased when combined with Idelalisib.Approved
IfenprodilIfenprodil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
IferanserinIferanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ImagabalinImagabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ImatinibThe metabolism of Hydrocodone can be decreased when combined with Imatinib.Approved
ImidafenacinThe risk or severity of adverse effects can be increased when Imidafenacin is combined with Hydrocodone.Approved, Investigational
ImipramineThe metabolism of Hydrocodone can be decreased when combined with Imipramine.Approved
Imipramine oxideImipramine oxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
IndalpineIndalpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Hydrocodone.Approved
IndinavirThe metabolism of Hydrocodone can be decreased when combined with Indinavir.Approved
IndiplonIndiplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Iofetamine I-123The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Iofetamine I-123.Approved
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Hydrocodone.Approved
IprazochromeIprazochrome may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
IprindoleIprindole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
IproclozideIproclozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
IproniazidIproniazid may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
IsavuconazoleThe metabolism of Hydrocodone can be decreased when combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Hydrocodone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinIsepamicin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
IsocarboxazidIsocarboxazid may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
IsoniazidThe metabolism of Hydrocodone can be decreased when combined with Isoniazid.Approved, Investigational
IsopropamideThe risk or severity of adverse effects can be increased when Isopropamide is combined with Hydrocodone.Approved, Vet Approved
IsosorbideThe therapeutic efficacy of Isosorbide can be decreased when used in combination with Hydrocodone.Approved, Investigational
ItraconazoleThe metabolism of Hydrocodone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe metabolism of Hydrocodone can be decreased when combined with Ivacaftor.Approved
IvermectinThe metabolism of Hydrocodone can be decreased when combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Hydrocodone can be decreased when it is combined with Ivosidenib.Approved, Investigational
IxabepiloneThe metabolism of Hydrocodone can be decreased when combined with Ixabepilone.Approved, Investigational
JosamycinThe metabolism of Hydrocodone can be decreased when combined with Josamycin.Approved, Investigational
KanamycinKanamycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
KetanserinKetanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
KetoconazoleThe metabolism of Hydrocodone can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Hydrocodone can be decreased when combined with Kitasamycin.Experimental
KOS-1584The metabolism of Hydrocodone can be decreased when combined with KOS-1584.Investigational
L-TryptophanL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Labetalol resulting in a loss in efficacy.Approved
LacosamideLacosamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Hydrocodone.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Hydrocodone.Approved
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LanicemineLanicemine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
LanreotideThe metabolism of Hydrocodone can be decreased when combined with Lanreotide.Approved
LansoprazoleThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Lansoprazole resulting in a loss in efficacy.Approved, Investigational
LapatinibThe metabolism of Hydrocodone can be decreased when combined with Lapatinib.Approved, Investigational
LasmiditanLasmiditan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
LestaurtinibThe metabolism of Hydrocodone can be decreased when combined with Lestaurtinib.Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Hydrocodone.Approved
LincomycinLincomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LisdexamfetamineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Lisdexamfetamine.Approved, Investigational
LisurideLisuride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Lithium carbonateLithium carbonate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Lithium cationLithium cation may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
LofepramineLofepramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
LofexidineLofexidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LomitapideThe metabolism of Hydrocodone can be decreased when combined with Lomitapide.Approved, Investigational
LopinavirThe metabolism of Hydrocodone can be decreased when combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LorcaserinLorcaserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LormetazepamLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LorpiprazoleThe serum concentration of Hydrocodone can be increased when it is combined with Lorpiprazole.Approved
LortalamineLortalamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Lorvotuzumab mertansineThe metabolism of Hydrocodone can be decreased when combined with Lorvotuzumab mertansine.Investigational
LovastatinThe metabolism of Hydrocodone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Hydrocodone.Approved, Investigational
LuliconazoleThe metabolism of Hydrocodone can be decreased when combined with Luliconazole.Approved
LumacaftorThe serum concentration of Hydrocodone can be decreased when it is combined with Lumacaftor.Approved
LumateperoneLumateperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
LumefantrineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Lumefantrine resulting in a loss in efficacy.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LymecyclineLymecycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Investigational, Withdrawn
m-Chlorophenylpiperazinem-Chlorophenylpiperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Magnesium acetateMagnesium acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium acetate tetrahydrateMagnesium acetate tetrahydrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium Aluminum SilicateMagnesium Aluminum Silicate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium aspartateMagnesium aspartate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Magnesium carbonateMagnesium carbonate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Magnesium cationMagnesium cation may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Nutraceutical
Magnesium chlorideMagnesium chloride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium citrateMagnesium citrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium gluconateMagnesium gluconate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Magnesium glycinateMagnesium glycinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium hydroxideMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Magnesium orotateMagnesium orotate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Magnesium oxideMagnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Hydrocodone.Experimental
Magnesium phosphateMagnesium phosphate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Magnesium silicateMagnesium silicate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium stearateMagnesium stearate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Magnesium sulfateMagnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ManidipineThe metabolism of Hydrocodone can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Hydrocodone.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Hydrocodone.Experimental
MazindolMazindol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MebanazineMebanazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Mebeverine is combined with Hydrocodone.Approved, Investigational
MebicarMebicar may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MebutamateMebutamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MebutizideThe therapeutic efficacy of Mebutizide can be decreased when used in combination with Hydrocodone.Experimental
MecamylamineMecamylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MedazepamMedazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
MedifoxamineMedifoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Medroxyprogesterone acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Mefloquine resulting in a loss in efficacy.Approved, Investigational
MefrusideThe therapeutic efficacy of Mefruside can be decreased when used in combination with Hydrocodone.Experimental
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Nutraceutical, Vet Approved
MelitracenMelitracen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Investigational
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MepartricinThe metabolism of Hydrocodone can be decreased when combined with Mepartricin.Experimental
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Hydrocodone.Approved
MephedroneThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Mephedrone.Investigational
MephenesinMephenesin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MephenoxaloneMephenoxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MephentermineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Mephentermine.Approved
MephenytoinMephenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Withdrawn
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MeptazinolMeptazinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MersalylThe therapeutic efficacy of Mersalyl can be decreased when used in combination with Hydrocodone.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MetergolineMetergoline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MethacyclineMethacycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MethamphetamineMethamphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydrocodone.Approved, Investigational
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Withdrawn
MetharbitalMetharbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
MethazolamideThe therapeutic efficacy of Methazolamide can be decreased when used in combination with Hydrocodone.Approved
MethimazoleThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Methimazole resulting in a loss in efficacy.Approved
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethotrimeprazineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
MethoxyphenamineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Methoxyphenamine.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Hydrocodone.Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Hydrocodone.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Hydrocodone.Approved
Methylene blueMethylene blue may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MethylpentynolMethylpentynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MethylphenidateMethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethylprednisoloneThe metabolism of Hydrocodone can be decreased when combined with Methylprednisolone.Approved, Vet Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Hydrocodone.Approved
MethylthioniniumThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Methylthioninium.Experimental, Investigational
MethyprylonMethyprylon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
MethysergideMethysergide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MeticraneThe therapeutic efficacy of Meticrane can be decreased when used in combination with Hydrocodone.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydrocodone.Approved
MetoclopramideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Hydrocodone.Approved, Investigational
MetocurineMetocurine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Metocurine IodideMetocurine Iodide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Hydrocodone.Approved
MetyraponeThe serum concentration of Hydrocodone can be decreased when it is combined with Metyrapone.Approved, Investigational
MetyrosineHydrocodone may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MibefradilThe metabolism of Hydrocodone can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Hydrocodone can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinMicronomicin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MidecamycinThe metabolism of Hydrocodone can be decreased when combined with Midecamycin.Approved
MidomafetamineMidomafetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Hydrocodone can be decreased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe metabolism of Hydrocodone can be decreased when combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MinaprineMinaprine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Hydrocodone.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MiocamycinThe metabolism of Hydrocodone can be decreased when combined with Miocamycin.Experimental
MirabegronThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Mirabegron resulting in a loss in efficacy.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Mirvetuximab SoravtansineThe metabolism of Hydrocodone can be decreased when combined with Mirvetuximab Soravtansine.Investigational
MitemcinalThe metabolism of Hydrocodone can be decreased when combined with Mitemcinal.Investigational
MitotaneThe serum concentration of Hydrocodone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MK-212MK-212 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
MMDAMMDA may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ModafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MoperoneMoperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MoricizineMoricizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MosapramineMosapramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MosaprideMosapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
MRK-409MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Hydrocodone.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineN-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
NafcillinThe serum concentration of Hydrocodone can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylNaftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
NaloxoneThe metabolism of Hydrocodone can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Naltrexone.Approved, Investigational, Vet Approved
NaluzotanNaluzotan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
NaratriptanNaratriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
NaronaprideNaronapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
NatamycinThe metabolism of Hydrocodone can be decreased when combined with Natamycin.Approved
NeamineNeamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
NefazodoneThe metabolism of Hydrocodone can be decreased when combined with Nefazodone.Approved, Withdrawn
NefiracetamNefiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
NelfinavirThe metabolism of Hydrocodone can be decreased when combined with Nelfinavir.Approved
NeocitrullamonNeocitrullamon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
NeomycinNeomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
NetilmicinNetilmicin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
NetupitantThe metabolism of Hydrocodone can be decreased when combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Hydrocodone can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
NiaprazineNiaprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
NicardipineThe metabolism of Hydrocodone can be decreased when combined with Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Nicomorphine.Experimental
NifedipineThe metabolism of Hydrocodone can be decreased when combined with Nifedipine.Approved
NilotinibThe metabolism of Hydrocodone can be decreased when combined with Nilotinib.Approved, Investigational
NisoxetineNisoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
NomifensineNomifensine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
NordazepamNordazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
NorgestimateThe serum concentration of Hydrocodone can be decreased when it is combined with Norgestimate.Approved, Investigational
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
NutmegThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Nutmeg.Approved
NystatinThe metabolism of Hydrocodone can be decreased when combined with Nystatin.Approved, Vet Approved
OctamoxinOctamoxin may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
OctreotideThe metabolism of Hydrocodone can be decreased when combined with Octreotide.Approved, Investigational
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
OlaparibThe metabolism of Hydrocodone can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Hydrocodone can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OmeprazoleThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Omeprazole resulting in a loss in efficacy.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OpipramolOpipramol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
OrphenadrineThe metabolism of Hydrocodone can be decreased when combined with Orphenadrine.Approved
OrvepitantOrvepitant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
OsimertinibThe serum concentration of Hydrocodone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Ospemifene resulting in a loss in efficacy.Approved, Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Hydrocodone.Experimental, Investigational
OxaflozaneOxaflozane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
OxaprotilineOxaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxcarbazepineOxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxiracetamOxiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
OxitriptanOxitriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Hydrocodone.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxybutyninThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Oxybutynin resulting in a loss in efficacy.Approved, Investigational
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
OxypertineOxypertine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Hydrocodone.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Hydrocodone.Investigational, Withdrawn
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydrocodone.Approved
OxytetracyclineOxytetracycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe metabolism of Hydrocodone can be decreased when combined with Palbociclib.Approved, Investigational
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PalonosetronPalonosetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PancuroniumPancuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PanobinostatThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Panobinostat resulting in a loss in efficacy.Approved, Investigational
PantoprazoleThe serum concentration of Hydrocodone can be decreased when it is combined with Pantoprazole.Approved
ParaldehydeParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ParamethadioneParamethadione may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ParamethasoneThe metabolism of Hydrocodone can be decreased when combined with Paramethasone.Approved
PargylinePargyline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ParomomycinParomomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ParoxetineParoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PasireotideThe metabolism of Hydrocodone can be decreased when combined with Pasireotide.Approved
PatupiloneThe metabolism of Hydrocodone can be decreased when combined with Patupilone.Experimental, Investigational
PazopanibThe metabolism of Hydrocodone can be decreased when combined with Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Peginterferon alfa-2b resulting in a loss in efficacy.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.Approved
PenbutololPenbutolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PenfluridolPenfluridol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PenimepicyclinePenimepicycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Hydrocodone.Experimental
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Penthienate is combined with Hydrocodone.Experimental
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydrocodone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PergolidePergolide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved, Withdrawn
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenacemidePhenacemide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenazocinePhenazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PhencyclidinePhencyclidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
PhenelzinePhenelzine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenelzineThe metabolism of Hydrocodone can be decreased when combined with Phenelzine.Approved
PhenethylaminePhenethylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PheneturidePheneturide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Hydrocodone.Experimental
PhenibutPhenibut may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PheniprazinePheniprazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Hydrocodone.Approved, Withdrawn
PhenoperidinePhenoperidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PhenoxypropazinePhenoxypropazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
PhenprobamatePhenprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PhensuximidePhensuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenterminePhentermine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
PhenylbutazoneThe serum concentration of Hydrocodone can be decreased when it is combined with Phenylbutazone.Approved, Vet Approved
Phenylbutyric acidThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Phenylbutyric acid resulting in a loss in efficacy.Approved, Investigational
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PiclozotanPiclozotan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Hydrocodone.Approved
PimavanserinPimavanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PimecrolimusThe metabolism of Hydrocodone can be decreased when combined with Pimecrolimus.Approved, Investigational
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PinazepamPinazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PindololPindolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PioglitazoneThe serum concentration of Hydrocodone can be decreased when it is combined with Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PipecuroniumPipecuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PipenzolateThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Hydrocodone.Experimental
PiperaquineThe metabolism of Hydrocodone can be decreased when combined with Piperaquine.Approved, Investigational
PiperidolateThe risk or severity of adverse effects can be increased when Piperidolate is combined with Hydrocodone.Experimental
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.Approved
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Hydrocodone.Approved
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PirlimycinPirlimycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
PirlindolePirlindole may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PitolisantThe serum concentration of Hydrocodone can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabinePivagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PivhydrazinePivhydrazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Hydrocodone.Approved, Investigational
PlazomicinPlazomicin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Hydrocodone.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Poldine is combined with Hydrocodone.Experimental
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Hydrocodone.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hydrocodone.Approved, Vet Approved
Polymyxin B SulfatePolymyxin B Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Hydrocodone.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PosaconazoleThe metabolism of Hydrocodone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe therapeutic efficacy of Potassium can be decreased when used in combination with Hydrocodone.Approved, Experimental
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Hydrocodone.Approved, Investigational
Potassium cationThe therapeutic efficacy of Potassium cation can be decreased when used in combination with Hydrocodone.Approved, Investigational
Potassium CitrateThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Hydrocodone.Approved, Investigational, Vet Approved
PramipexoleHydrocodone may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
PrednicarbateThe serum concentration of Hydrocodone can be decreased when it is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe metabolism of Hydrocodone can be decreased when combined with Prednisolone.Approved, Vet Approved
PrednisoneThe metabolism of Hydrocodone can be decreased when combined with Prednisone.Approved, Vet Approved
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
PridinolPridinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Prifinium is combined with Hydrocodone.Experimental
PrimaquineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Primaquine resulting in a loss in efficacy.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ProcainamideProcainamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydrocodone.Approved
ProgabideProgabide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ProgesteroneThe metabolism of Hydrocodone can be decreased when combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PropafenoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Propafenone resulting in a loss in efficacy.Approved
PropanididPropanidid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydrocodone.Approved
PropericiazinePropericiazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PropiomazinePropiomazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PropiopromazinePropiopromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Hydrocodone.Approved, Investigational
PropofolThe metabolism of Hydrocodone can be decreased when combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Propranolol resulting in a loss in efficacy.Approved, Investigational
ProthipendylProthipendyl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ProxibarbalProxibarbal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Hydrocodone.Approved
PRX-08066PRX-08066 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PseudoephedrineThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Pseudoephedrine.Approved
PsilocybinePsilocybine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PuromycinPuromycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PyrantelPyrantel may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PyrithyldionePyrithyldione may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Hydrocodone.Approved
QuinidineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Quinidine resulting in a loss in efficacy.Approved, Investigational
QuinineQuinine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
QuinupramineQuinupramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
QuinupristinThe metabolism of Hydrocodone can be decreased when combined with Quinupristin.Approved
RabeprazoleThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Rabeprazole resulting in a loss in efficacy.Approved, Investigational
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RamosetronRamosetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RanitidineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Ranitidine resulting in a loss in efficacy.Approved
RapacuroniumRapacuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
RasagilineRasagiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ReboxetineReboxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RegorafenibThe metabolism of Hydrocodone can be decreased when combined with Regorafenib.Approved
RemacemideRemacemide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
RenzaprideRenzapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RepinotanRepinotan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ReposalReposal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Revefenacin is combined with Hydrocodone.Investigational
RheinThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Rhein resulting in a loss in efficacy.Experimental
RibostamycinRibostamycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RidaforolimusThe metabolism of Hydrocodone can be decreased when combined with Ridaforolimus.Investigational
RifabutinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Hydrocodone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe metabolism of Hydrocodone can be decreased when combined with Rilpivirine.Approved
RiluzoleRiluzole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RimexoloneThe serum concentration of Hydrocodone can be decreased when it is combined with Rimexolone.Approved
RisperidoneThe metabolism of Hydrocodone can be decreased when combined with Risperidone.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RitobegronThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Ritobegron.Investigational
RitonavirThe metabolism of Hydrocodone can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanRizatriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RociverineThe risk or severity of adverse effects can be increased when Rociverine is combined with Hydrocodone.Experimental
RocuroniumRocuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RofecoxibThe serum concentration of Hydrocodone can be decreased when it is combined with Rofecoxib.Approved, Investigational, Withdrawn
RokitamycinThe metabolism of Hydrocodone can be decreased when combined with Rokitamycin.Experimental
RolapitantThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Rolapitant resulting in a loss in efficacy.Approved, Investigational
RolipramRolipram may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RolitetracyclineRolitetracycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RolofyllineThe therapeutic efficacy of Rolofylline can be decreased when used in combination with Hydrocodone.Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
RopiniroleRopinirole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RotigotineRotigotine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RP-5063RP-5063 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RucaparibThe metabolism of Hydrocodone can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideRufinamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SafinamideSafinamide may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SafrazineSafrazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
SagopiloneThe metabolism of Hydrocodone can be decreased when combined with Sagopilone.Investigational
SaquinavirThe metabolism of Hydrocodone can be decreased when combined with Saquinavir.Approved, Investigational
SaracatinibThe metabolism of Hydrocodone can be decreased when combined with Saracatinib.Investigational
SaredutantSaredutant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
SarilumabThe metabolism of Hydrocodone can be decreased when combined with Sarilumab.Approved, Investigational
SarpogrelateSarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
SelamectinThe metabolism of Hydrocodone can be decreased when combined with Selamectin.Vet Approved
SelegilineSelegiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Hydrocodone.Approved
SerotoninSerotonin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Nutraceutical
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
SertralineSertraline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
SibutramineSibutramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Withdrawn
SiltuximabThe serum concentration of Hydrocodone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe metabolism of Hydrocodone can be decreased when combined with Simeprevir.Approved
SirolimusThe metabolism of Hydrocodone can be decreased when combined with Sirolimus.Approved, Investigational
SisomicinSisomicin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hydrocodone.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Hydrocodone.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Hydrocodone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydrocodone.Approved
SolithromycinThe metabolism of Hydrocodone can be decreased when combined with Solithromycin.Investigational
SomatostatinThe metabolism of Hydrocodone can be decreased when combined with Somatostatin.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Hydrocodone.Approved
SpiradolineThe therapeutic efficacy of Spiradoline can be decreased when used in combination with Hydrocodone.Investigational
SpironolactoneThe therapeutic efficacy of Spironolactone can be decreased when used in combination with Hydrocodone.Approved
St. John's WortSt. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Nutraceutical
StiripentolThe metabolism of Hydrocodone can be decreased when combined with Stiripentol.Approved
StreptomycinStreptomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
StyramateStyramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
SuccinylcholineSuccinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SulconazoleThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Sulconazole resulting in a loss in efficacy.Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SulthiameSulthiame may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
SultoprideSultopride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
SumatriptanSumatriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SuvorexantHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrolimusThe metabolism of Hydrocodone can be decreased when combined with Tacrolimus.Approved, Investigational
TalbutalTalbutal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
TalopramTalopram may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TD-8954TD-8954 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Tedizolid phosphateTedizolid phosphate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TegaserodTegaserod may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Hydrocodone can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Hydrocodone can be decreased when combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TemsirolimusThe metabolism of Hydrocodone can be decreased when combined with Temsirolimus.Approved
TerbinafineThe serum concentration of Hydrocodone can be decreased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Hydrocodone can be decreased when it is combined with Terfenadine.Approved, Withdrawn
TestosteroneThe serum concentration of Hydrocodone can be decreased when it is combined with Testosterone.Approved, Investigational
TetracosactideThe serum concentration of Hydrocodone can be decreased when it is combined with Tetracosactide.Approved
TetracyclineTetracycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
TetrahydrocannabivarinTetrahydrocannabivarin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
TetrahydropalmatineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
TetrazepamTetrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ThalidomideHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe therapeutic efficacy of Theobromine can be decreased when used in combination with Hydrocodone.Approved, Investigational
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ThiazinamThiazinam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ThiethylperazineThiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
ThiocolchicosideThiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ThiopropazateThiopropazate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ThioproperazineThioproperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Hydrocodone.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TianeptineTianeptine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Ticagrelor resulting in a loss in efficacy.Approved
TiclopidineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Ticlopidine resulting in a loss in efficacy.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Hydrocodone.Withdrawn
Tiemonium iodideThe risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Hydrocodone.Experimental
TigecyclineTigecycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TildipirosinThe metabolism of Hydrocodone can be decreased when combined with Tildipirosin.Vet Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
TilidineTilidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
TilmicosinThe metabolism of Hydrocodone can be decreased when combined with Tilmicosin.Investigational, Vet Approved
TimepidiumThe risk or severity of adverse effects can be increased when Timepidium is combined with Hydrocodone.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Hydrocodone.Approved
TipranavirThe metabolism of Hydrocodone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TobramycinTobramycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TocilizumabThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.Approved
TofisopamTofisopam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TolperisoneTolperisone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydrocodone.Approved, Investigational
TolvaptanThe therapeutic efficacy of Tolvaptan can be decreased when used in combination with Hydrocodone.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Hydrocodone.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TramiprosateTramiprosate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
TranylcypromineTranylcypromine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TranylcypromineThe metabolism of Hydrocodone can be decreased when combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe metabolism of Hydrocodone can be decreased when combined with Trastuzumab emtansine.Approved, Investigational
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TriamcinoloneThe serum concentration of Hydrocodone can be decreased when it is combined with Triamcinolone.Approved, Vet Approved
TriamtereneThe therapeutic efficacy of Triamterene can be decreased when used in combination with Hydrocodone.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Tricaine methanesulfonateTricaine methanesulfonate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Hydrocodone.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TriclofosTriclofos may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Tridihexethyl is combined with Hydrocodone.Withdrawn
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TrifluperidolTrifluperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydrocodone.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Trimebutine is combined with Hydrocodone.Approved
TrimethadioneTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydrocodone.Approved, Investigational
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TroglitazoneThe serum concentration of Hydrocodone can be decreased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe metabolism of Hydrocodone can be decreased when combined with Troleandomycin.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Hydrocodone.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydrocodone.Approved, Investigational
TropisetronTropisetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hydrocodone.Approved
TubocurarineTubocurarine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TylosinThe metabolism of Hydrocodone can be decreased when combined with Tylosin.Vet Approved
TylvalosinThe metabolism of Hydrocodone can be decreased when combined with Tylvalosin.Vet Approved
UlaritideThe therapeutic efficacy of Ularitide can be decreased when used in combination with Hydrocodone.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydrocodone.Approved
UrapidilUrapidil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
VabicaserinVabicaserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ValerianValerian may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Experimental, Investigational
ValnoctamideValnoctamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Valproate bismuthThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Valproate bismuth.Approved
Valproic AcidThe metabolism of Hydrocodone can be decreased when combined with Valproic Acid.Approved, Investigational
ValpromideValpromide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
VancomycinVancomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
VapreotideThe metabolism of Hydrocodone can be decreased when combined with Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
VemurafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
VeraliprideVeralipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
VerapamilThe metabolism of Hydrocodone can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
VilazodoneVilazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ViloxazineViloxazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
VinbarbitalVinbarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
VinblastineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Vinblastine resulting in a loss in efficacy.Approved
VinorelbineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Vinorelbine resulting in a loss in efficacy.Approved, Investigational
VinpocetineVinpocetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Vinyl etherVinyl ether may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
VinylbitalVinylbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
VoriconazoleThe metabolism of Hydrocodone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
WortmanninWortmannin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Hydrocodone.Experimental
XP19986XP19986 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
YKP-1358YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
YohimbineYohimbine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZileutonThe metabolism of Hydrocodone can be decreased when combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
ZiprasidoneThe metabolism of Hydrocodone can be decreased when combined with Ziprasidone.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
ZolmitriptanZolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

References

Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, "Morphinone reductase for the preparation of hydromorphone and hydrocodone." U.S. Patent US5571685, issued November, 1990.

US5571685
General References
Not Available
External Links
Human Metabolome Database
HMDB0015091
KEGG Drug
D08045
KEGG Compound
C08024
PubChem Compound
5284569
PubChem Substance
46506225
ChemSpider
4447623
BindingDB
50386689
ChEBI
5779
ChEMBL
CHEMBL1457
Therapeutic Targets Database
DAP000253
PharmGKB
PA449900
RxList
RxList Drug Page
Wikipedia
Hydrocodone
ATC Codes
R05DA03 — Hydrocodone
AHFS Codes
  • 48:08.00 — Antitussives
MSDS
Download (48.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentFracture, Ankle1
0WithdrawnTreatmentPain / Painful musculoskeletal conditions1
1Active Not RecruitingTreatmentHead and Neck Carcinoma / Oral Mucositis1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHepatic Impairment1
1CompletedNot AvailableImpaired Renal Function1
1CompletedNot AvailablePain1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentDrug Abuse1
1WithdrawnTreatmentOpioid-Related Disorders / Pain, Acute / Postoperative pain2
2CompletedNot AvailableDegenerative Joint Disease1
2CompletedNot AvailablePostoperative pain1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain6
2Not Yet RecruitingTreatmentPain1
2RecruitingTreatmentCorneal Abrasions / Eye Trauma1
2RecruitingTreatmentPainful musculoskeletal conditions1
3CompletedPreventionNausea / Pain / Vomiting1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedTreatmentBack Pain Lower Back Chronic1
3CompletedTreatmentChronic Low Back Pain (CLBP)4
3CompletedTreatmentChronic Nonmalignant and Nonneuropathic Pain1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentModerate to Severe Chronic, Non-malignant Pain1
3CompletedTreatmentNausea / Pain / Vomiting1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPain3
3CompletedTreatmentPain, Chronic1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingTreatmentOpioids Use / Shoulder Pain1
3RecruitingTreatmentPostoperative pain / Surgery, Outpatient1
3TerminatedNot AvailablePost Operative Pain1
4CompletedNot AvailablePain, Chronic1
4CompletedBasic ScienceDriving Behavior1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular / Dementias / Pain1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentOpioids Use / Postoperative pain1
4CompletedTreatmentPain2
4CompletedTreatmentToothache1
4Enrolling by InvitationTreatmentCarpal Tunnel / Cystic tumour of the ganglia / De Quervain's Disease / Trigger Finger1
4Not Yet RecruitingTreatmentPain1
4Not Yet RecruitingTreatmentPain Control After Functional Endoscopic Sinus Surgery and Septoplasty1
4RecruitingSupportive CareCarpal Tunnel1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingTreatmentBody Weight Changes / Postoperative Hemorrhages / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentPain1
4RecruitingTreatmentPain Management1
4RecruitingTreatmentRib Fracture Multiple / Rib Fractures1
4SuspendedTreatmentRotator Cuff Syndrome1
4TerminatedTreatmentAdverse Reaction to Drug / Obstructive Sleep Apnea (OSA) / Recurrent Tonsillitis / Sleep Disordered Breathing (SDB)1
4TerminatedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedTreatmentCancer, Breast / Postoperative pain1
Not AvailableCompletedTreatmentChildren / Laceration / Pain / Procedures1
Not AvailableCompletedTreatmentContraception / Inhalation of Nitrous Oxide1
Not AvailableCompletedTreatmentDrug Interactions1
Not AvailableCompletedTreatmentSkin Laxity1
Not AvailableNot Yet RecruitingTreatmentNon-steroidal Ant Inflammatory Drugs / Opioids Use / Rhinoplasty1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableWithdrawnSupportive CareToothache1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Abbott Laboratories Ltd.
  • Actavis Group
  • AG Marin Pharmaceuticals
  • Aidarex Pharmacuticals LLC
  • Altura Pharmaceuticals Inc.
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Andrx Laboratories Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Auriga Pharmaceuticals LLC
  • BASF Corp.
  • Blenheim Pharmacal
  • Brighton Pharmaceuticals
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Caremark LLC
  • Comfortpak Inc.
  • Corepharma LLC
  • Cypress Pharmaceutical Inc.
  • D.M. Graham Laboratories Inc.
  • Dartmouth Pharmaceuticals Inc.
  • Deltex Pharmaceuticals Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Econolab Inc.
  • ECR Pharmaceuticals
  • Edwards Pharmaceuticals
  • Endo Pharmaceuticals Inc.
  • Everett Laboratories Inc.
  • Gm Pharmaceuticals Inc.
  • Great Southern Laboratories
  • H.J. Harkins Co. Inc.
  • Hampton Laine LLC
  • Hawthorn Pharmaceuticals
  • Heartland Repack Services LLC
  • Hi Tech Pharmacal Co. Inc.
  • Innoviant Pharmacy Inc.
  • Iopharm Laboratories Inc.
  • Ivax Pharmaceuticals
  • JMI Daniels Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • King Pharmaceuticals Inc.
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Larken Laboratories Inc.
  • Liberty Pharmaceuticals
  • Llorens Pharmaceutical
  • Magna Pharmaceuticals
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Marnel Pharmaceuticals Inc.
  • Mason Pharmaceuticals Inc.
  • Mckesson Corp.
  • MCR American Pharmaceuticals Inc.
  • Medvantx Inc.
  • Mikart Inc.
  • Monarch Pharmacy
  • Monte Sano Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nippon Protein Co. Ltd.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Pamlab LLC
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Poly Pharmaceuticals Inc.
  • Prasco Labs
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Provident Pharmaceuticals LLC
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Schwarz Pharma Inc.
  • Seatrace Pharmaceuticals Inc.
  • Southwood Pharmaceuticals
  • Sovereign Pharmaceuticals Ltd.
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Superior Pharmeceuticals
  • Talbert Medical Management Corp.
  • Teamm Pharmaceuticals Inc.
  • UCB Pharma
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Veratex Corp.
  • Victory Pharma
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
  • WraSer Pharmaceuticals
  • Xanodyne Pharmaceuticals Inc.
  • Zyber Pharmaceuticals
Dosage forms
FormRouteStrength
LiquidOral
TabletOral5 mg
SolutionOral
TabletOral
TabletOral5 mg/1
Suspension, extended releaseOral
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral60 mg/1
Tablet, extended releaseOral80 mg/1
SyrupOral
SyrupOral5 mg
SyrupOral1 mg
Kit
CreamTopical
Capsule, extended releaseOral
SuspensionOral
Tablet, extended releaseOral
Tablet, coatedOral
Tablet, film coatedOral
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral50 mg/1
Prices
Unit descriptionCostUnit
Hydrocodone-Acetaminophen 7.5-500 mg/15ml Solution 473ml Bottle60.97USD bottle
Hydrocodone-Ibuprofen 7.5-200 mg tablet1.13USD tablet
Hydrocodone-Acetaminophen 10-750 mg tablet1.1USD tablet
Hydrocodone-Acetaminophen 7.5-325 mg tablet0.63USD tablet
Hydrocodone-Acetaminophen 10-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 5-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 10-660 mg tablet0.53USD tablet
Hydrocodone-Acetaminophen 10-500 mg tablet0.5USD tablet
Hydrocodone-Acetaminophen 10-650 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 7.5-500 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 2.5-500 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 7.5-750 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 5-500 mg tablet0.4USD tablet
Hydrocodone-Acetaminophen 7.5-650 mg tablet0.16USD tablet
Hydrocodone-Homatropine 5-1.5 mg/5ml Syrup0.15USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9265760No2013-07-232033-07-23Us
US6599531No1997-06-102017-06-10Us
US6348216No1997-06-102017-06-10Us
US6228398No1999-11-012019-11-01Us
US8309060No2003-11-202023-11-20Us
US6488963No1997-06-242017-06-24Us
US9060940No2001-10-302021-10-30Us
US8808740No2011-12-212031-12-21Us
US6733783No2001-10-302021-10-30Us
US9095614No2007-08-242027-08-24Us
US9095615No2007-08-242027-08-24Us
US8361499No2001-10-302021-10-30Us
US9084816No2007-08-242027-08-24Us
US9205056No2001-10-302021-10-30Us
US8647667No2001-10-302021-10-30Us
US9198863No2001-10-302021-10-30Us
US9289391No2001-10-302021-10-30Us
US9056052No2001-10-302021-10-30Us
US8529948No2002-08-062022-08-06Us
US8551520No2001-10-302021-10-30Us
US9023401No2001-10-302021-10-30Us
US9326982No2013-07-252033-07-25Us
US6902742No1999-11-012019-11-01Us
US9132096No2014-09-122034-09-12Us
US9492389No2007-08-242027-08-24Us
US9492391No2007-08-242027-08-24Us
US9549907No2015-11-132035-11-13Us
US9572804No2000-10-302020-10-30Us
US9669023No2000-10-302020-10-30Us
US9486412No2007-08-242027-08-24Us
US9669024No2000-10-302020-10-30Us
US9572779No2011-12-212031-12-21Us
US9486413No2007-08-242027-08-24Us
US9517236No2000-10-302020-10-30Us
US9492390No2007-08-242027-08-24Us
US9675611No2000-10-302020-10-30Us
US9682077No2000-10-302020-10-30Us
US9545380No2007-08-242027-08-24Us
US9333201No2013-07-252033-07-25Us
US9610286No2013-07-252033-07-25Us
US9452163No2014-09-122034-09-12Us
US9486451No2014-09-122034-09-12Us
US9339499No2013-07-252033-07-25Us
US9421200No2013-07-252033-07-25Us
US9433619No2013-07-252033-07-25Us
US9675610No2003-06-162023-06-16Us
US9572803No2007-09-132027-09-13Us
US9216176No2007-09-132027-09-13Us
US8445018No2009-07-312029-07-31Us
US9713611No2014-09-122034-09-12Us
US9763933No2007-08-242027-08-24Us
US9770416No2007-08-242027-08-24Us
US9775809No2007-08-242027-08-24Us
US9750703No2011-12-212031-12-21Us
US9861584No2011-12-212031-12-21Us
US9872837No2011-12-212031-12-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)198 °CPhysProp
water solubilityInsolubleNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.797 mg/mLALOGPS
logP2.13ALOGPS
logP1.96ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)18ChemAxon
pKa (Strongest Basic)8.61ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.74 m3·mol-1ChemAxon
Polarizability32.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9984
Caco-2 permeable+0.8621
P-glycoprotein substrateSubstrate0.8253
P-glycoprotein inhibitor IInhibitor0.6425
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterInhibitor0.6604
CYP450 2C9 substrateNon-substrate0.8546
CYP450 2D6 substrateSubstrate0.8997
CYP450 3A4 substrateSubstrate0.8168
CYP450 1A2 substrateNon-inhibitor0.8207
CYP450 2C9 inhibitorNon-inhibitor0.9412
CYP450 2D6 inhibitorInhibitor0.6629
CYP450 2C19 inhibitorNon-inhibitor0.8402
CYP450 3A4 inhibitorNon-inhibitor0.7625
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8675
Ames testNon AMES toxic0.7735
CarcinogenicityNon-carcinogens0.9419
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.0914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9024
hERG inhibition (predictor II)Non-inhibitor0.8165
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.3 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0005-6970000000-3ba3e105098639cd6091
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0009000000-f21858df54194757e2d9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0009000000-9b129b5d29df52345272
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0649000000-82623b23b75f0a0b232d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0920000000-b67ff5a32d0ddd40c4c7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006t-0900000000-0277ba7435a4081ab333
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0g6v-0900000000-b335c52fad1274cd28cb

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Isoquinolones and derivatives / Tetralins / Coumarans / Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / Trialkylamines / Ketones
show 5 more
Substituents
Morphinan / Phenanthrene / Isoquinolone / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Benzenoid
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound (CHEBI:5779)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. [PubMed:10640321]
  3. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875]
  4. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. [PubMed:2849950]
  5. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248]
  6. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Oct;212(2):193-203. doi: 10.1007/s00213-010-1942-4. Epub 2010 Jul 28. [PubMed:20665209]
  7. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. doi: 10.1016/j.drugalcdep.2008.05.007. Epub 2008 Jul 7. [PubMed:18606504]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875]
  2. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:32